Myosana Therapeutics, Inc. is leading the efforts in developing new gene therapies that will slow skeletal muscle degeneration and heart failure to improve the quality of life, increase longevity and reduce the disease burden of Duchenne muscular dystrophy (DMD) and other neuromuscular diseases.
Matthew Lumley Matthew Lumley
Matthew is a trained Cardiologist with a Ph.D. in cardiovascular physiology. He has extensive experience in the Bio-pharmaceutical field, with positions at Pfizer, as Medical Director of Rare Diseases and, more recently Moderna, where he was responsible for taking the first mRNA therapeutics for rare diseases into the clinic. Currently, Matthew is a Venture Partner at Medicxi.
Nick Whitehead Nick Whitehead Nick trained as a muscle physiologist and has more than 20 years experience in DMD muscle research. He is currently a Research Associate Professor in the Department of Physiology and Biophysics at the University of Washington. His innovative Muscle-Targeted, Non-Viral platform has the potential to provide a novel gene therapy treatment for DMD a wide-range of other neuromuscular and cardiac disorders.
Stan Froehner Stan Froehner Stan has decades of experience in muscle research and discovered the Syntrophin proteins, members of the Dystrophin complex in muscle. He has extensive research experience in DMD. He is currently a Professor of Physiology and Biophysics at the University of Washington. Stan was elected to the Washington State Academy of Sciences in 2013 and selected as a Fellow of the American Association for the Advancement of Sciences in 2017.